Bio-Implants Market

The bio-implants market was valued at US$ 127.59 billion in 2024 and is anticipated to reach US$ 223.06 billion by 2031, with an estimated CAGR of 8.3% from 2025 to 2031.

Analyst Perspective:

This report outlines growth opportunities based on current trends and factors driving the bio-implants market. Key contributors to the expanding bio-implants market include the rising incidence of chronic diseases, especially among the elderly, and increasing disposable incomes. The enhancement of healthcare infrastructure in both developed and developing nations is also expected to significantly boost the bio-implants market.

Global awareness regarding the benefits of cosmetic implants and advancements in technology has risen. The bio-implants market is experiencing growth worldwide, particularly due to the increasing prevalence of dental issues. Additionally, the demand for orthopedic implants and pacemakers is on the rise due to the growing incidence of cardiovascular and orthopedic conditions. In North America, sales of bio-implants are projected to increase, driven by a strong healthcare system, heightened awareness of cosmetic implants, and the presence of major industry players. Europe ranks as the second-largest bio-implants market globally, fueled by rapid technological progress in healthcare, a growing demand for non-invasive bio-implants, and an increasing elderly population. However, the high costs associated with bio-implant procedures and the need for proper utilization of bio-implant products pose challenges to market growth.

Market Overview:

Factors driving the growth of the bio-implants market include the rising incidence of bone degeneration in older adults, an increasing demand for minimally invasive surgical options, and a surge in lifestyle-related disorders. Furthermore, advancements in healthcare technology are expected to significantly influence the bio-implants market outlook in the coming years. Despite notable technological progress in healthcare, the rising prevalence of serious medical conditions has impeded the bio-implants market.

Strategic Insights Market Driver: Increasing Burden of Lifestyle Disorders Propel Market Growth

Lifestyle-related disorders such as diabetes, cardiovascular diseases, and osteoarthritis are becoming more common globally, leading to significant morbidity and mortality. Bio-implants, including stents and scaffolds, are emerging as viable alternatives to traditional permanent implants for treating these conditions. According to a 2021 article from the American Heart Association, approximately 40,000 children in the US undergo congenital heart surgery annually. The UK Factsheet January 2022 from the British Heart Foundation reported that around 7.6 million individuals live with heart and circulatory diseases, with nearly 4 million men and 3.6 million women affected in 2021. Consequently, the rising prevalence of cardiovascular diseases is driving the demand for early diagnosis and treatment, which is expected to boost the need for interventional cardiology procedures and cardiovascular bio-implants. Additionally, a significant increase in oral health issues is anticipated to elevate the demand for bio-implants. The World Health Organization (WHO) 2021 Global Burden of Disease Study indicated that oral diseases are projected to impact nearly half of the global population, with approximately 3.58 billion individuals affected by dental caries and other dental issues.

Moreover, bio-implants play a crucial role in managing and delivering specific medications for conditions like musculoskeletal disorders. A January 2021 article in Orthopedic Surgery noted that the prevalence of lumbar spondylolisthesis among middle-aged individuals in Beijing was 17.26% (15.98% in men and 18.80% in women), with women over 60 being particularly susceptible. The WHO reports that musculoskeletal injuries and diseases affect 1.71 billion people globally, making them a leading cause of disability. Projections suggest that by 2050, over 1 billion individuals will suffer from joint, muscle, bone, ligament, tendon, and spine diseases, up from about half a billion in 2020, according to a study published in The Lancet Rheumatology. The growing elderly population is rapidly increasing the number of individuals with musculoskeletal conditions and related functional limitations, leading to a higher demand for implant procedures and hospitalizations, thus propelling the bio-implants market.

Segmental Analysis:

The analysis of the bio-implants market has been conducted by examining the following segments: type, material, and end user.

By type, the bio-implants market is categorized into cardiovascular implants, orthopedic implants, dental implants, ophthalmic implants, and others. The cardiovascular implants segment accounted for a significant market share in 2023, driven by a surge in research and development aimed at creating innovative cardiac implant products. For instance, in February 2022, Abbott, a medical technology firm, announced the first patient implantation of a leadless dual-chamber pacemaker system as part of its AVEIR DR i2i pivotal clinical trial, marking a significant technological advancement in leadless pacemaker technology.

The bio-implants market, categorized by material, includes metals, ceramics, and polymers. The immediate-release capsules segment held the largest market share in 2023 and is expected to exhibit the highest CAGR during the forecast period. Metals are preferred for implant applications due to their exceptional mechanical strength, corrosion resistance, and biocompatibility. Titanium is a widely used material for orthopedic, dental, and cardiovascular implants due to its remarkable durability, lightweight nature, and compatibility with human tissue. Metals are also valued for specialized implant applications such as cardiac electrodes and neurological probes due to their malleability, electrical conductivity, and inertness. The increasing prevalence of chronic diseases and advancements in materials science and manufacturing techniques are driving the demand for biomaterial metals in bio-implants, solidifying their position as the leading material category in the bio-implants market.

By end user, the market is divided into hospitals & clinics and ambulatory surgical centers. The hospitals & clinics segment held a larger share of the bio-implants market in 2023 and is projected to register a higher CAGR from 2023 to 2031. Hospitals & clinics attract a large patient base, including those requiring specialized implant treatments, due to their comprehensive medical programs and multidisciplinary approach to patient care. Hospitals often collaborate with research centers and medical device manufacturers to access cutting-edge implant technologies. They play a crucial role in the bio-implants market by providing essential implant-related services and generating significant demand for bio-implant products and processes. Thus, the increasing number of hospitals & clinics, coupled with the rising demand for medical care, is expected to support the growth of this segment during the forecast period.

Regional Analysis:

The bio-implants market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The North American market was valued at US$ 50.51 billion in 2023 and is projected to reach US$ 96.69 billion by 2031, with an expected CAGR of 8.5% from 2023 to 2031. The market in North America is segmented into the US, Canada, and Mexico, with growth attributed to the rising prevalence of chronic diseases and improved healthcare infrastructure. Updated data from the Centers for Disease Control and Prevention (CDC) in July 2022 indicates that coronary artery disease is one of the most prevalent heart diseases, affecting approximately 20.1 million adults aged 20 and older in the US. Additionally, CDC data reveals that a heart attack occurs every 40 seconds, affecting nearly 805,000 individuals. The increasing incidence of chronic diseases is expected to drive the overall demand for bio-implants during the forecast period.

According to the Centers for Medicare and Medicaid Services, national healthcare spending is projected to reach US$ 6.2 trillion by 2028, growing at an average annual rate of 5.4% from 2019 to 2028. As national healthcare spending is expected to increase by 1.1 percentage points, the healthcare sector's share of the economy is anticipated to rise to 19.7% by 2028, outpacing the average annual GDP growth from 2019 to 2028. Consequently, the rising healthcare expenditure is expected to create opportunities for market players to develop bio-implants during the forecast period.

Europe holds the second-largest share of the bio-implants market in 2023, with growth attributed to technological advancements in healthcare, increased demand for non-surgical bio-implants, and a growing elderly population. The market growth in Europe is supported by government funding and healthcare initiatives, a rising incidence of orthopedic diseases, and increased research and development activities in healthcare. Furthermore, the growing number of cardiovascular surgeries due to the rising incidence of cardiovascular diseases in the region is driving the bio-implants market.

Asia Pacific is expected to exhibit the highest CAGR in the global bio-implants market from 2023 to 2031. The market growth in this region is driven by the increasing elderly population, rising disposable incomes, growing healthcare investments, and the expansion of market players, along with a rise in spinal cord injuries due to traffic accidents. Asia Pacific is experiencing significant growth, particularly in emerging markets like China and India. The expansion of healthcare infrastructure and increased investments in this sector to enhance patient services are propelling the bio-implants market in the region. For instance, a 2019 publication from Japan's Keio University reported that approximately 100,000 patients in Japan are paralyzed due to spinal cord injuries. However, the approval of iPS technology is expected to assist these patients in the near future, potentially creating opportunities in the bio-implants market. According to the United Nations Economic and Social Commission for Asia and the Department of Social Development in the Pacific, in 2016, over 12.4% of Asia's population was over 60 years old, a figure projected to reach 1.3 billion by 2050.

Bio-implants Market Report Scope Key Player Analysis:

Key players profiled in the bio-implants market report include LifeNet Health, Smith & Nephew, Arthrex, Inc., Clinic Lemanic, Alpha Bio Tec, MiMedx Group, Medtronic, St Jude Medical (Abbott), Stryker Corporation, DePuy Synthes, Biomet (Zimmer), Exactech, Inc., Cochlear Ltd, and Straumann AG.

Recent Developments:

Companies in the market are engaging in mergers and acquisitions. Below are some recent key developments based on company press releases:

1. In February 2023, CurvaFix, Inc., a medical device developer focused on repairing fractures in curved bones, launched its smaller diameter 7.5mm CurvaFix IM implant, designed to simplify surgical procedures and provide strong, stable fixation in small bones.
2. In June 2022, ZimVie introduced the FDA-approved T3 pro-engineered implants and Encode Emergence Healing Abutment in the US.
3. In June 2021, Intelligent Implants Ltd. received breakthrough designation from the US FDA for SmartFuse, an orthopedic implant technology designed to remotely stimulate, control, and monitor bone growth for real-time clinical decisions, indicated for first-use patients undergoing lumbar spinal fusion.
4. In February 2021, Medtronic launched the TYRX Absorbable Antibacterial Sheath, an absorbable, disposable antibacterial sheath designed for stabilizing a cardiac implantable electronic device or implanted neurostimulator.

This product will be delivered within 3-5 business days.